Clinical pharmacogenetics tumors

This chapter highlights some of the recent, major publications in the field of pharmacogenetics in RA and describes the implications of this field for future research and clinical care. The pharmacogenetics of three major non-biologic DMARDs, methotrexate (MTX), azathioprine, and sulfasalazine (SSZ), and three biologic DMARDs, the tumor necrosis factor antagonists, rituximab, and tocilizumab in RA, is reviewed. 

---